Amneal Pharmaceuticals Inc
F:2DT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Amneal Pharmaceuticals Inc
F:2DT
|
US |
|
PCI Biotech Holding ASA
OSE:PCIB
|
NO |
|
N
|
Netweb Technologies India Ltd
NSE:NETWEB
|
IN |
|
E
|
EUROKAI GmbH & Co KgaA
F:EUK3
|
DE |
Wall Street
Price Targets
2DT Price Targets Summary
Amneal Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for 2DT is 12.21 EUR with a low forecast of 10.84 EUR and a high forecast of 13 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is 2DT's stock price target?
Price Target
12.21
EUR
According to Wall Street analysts, the average 1-year price target for 2DT is 12.21 EUR with a low forecast of 10.84 EUR and a high forecast of 13 EUR.
What is Amneal Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
6%
For the last 14 years the compound annual growth rate for Amneal Pharmaceuticals Inc's revenue is 13%. The projected CAGR for the next 3 years is 6%.
What is Amneal Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
29%
For the last 14 years the compound annual growth rate for Amneal Pharmaceuticals Inc's operating income is 10%. The projected CAGR for the next 3 years is 29%.
What is Amneal Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
80%
For the last 14 years the compound annual growth rate for Amneal Pharmaceuticals Inc's net income is 1%. The projected CAGR for the next 3 years is 80%.
